# AnaptysBio (ANAB) — Analyst Forecast

ANAB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/anab/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 7 | 0 | 0 | 7 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $60.00 | $76.50 | $95.00 | 4 |

Last price $48.71 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 30, 2026 | JP Morgan | Maintained | Overweight | $60.00 |
| Sep 24, 2026 | HC Wainwright & Co. | Maintained | Buy | $95.00 |
| Sep 23, 2026 | Leerink Partners | Maintained | Outperform | $81.00 |
| Aug 25, 2026 | TD Cowen | Maintained | Buy | $70.00 |
| Aug 24, 2026 | HC Wainwright & Co. | Maintained | Buy | $95.00 |
| Jun 10, 2026 | HC Wainwright & Co. | Initiated Coverage | Buy | $95.00 |
| May 13, 2026 | Barclays | Maintained | Overweight | $75.00 |
| May 13, 2026 | UBS | Maintained | Buy | $76.00 |
| May 4, 2026 | Piper Sandler | Maintained | Overweight | $93.00 |
| Apr 28, 2026 | Leerink Partners | Maintained | Outperform | $85.00 |
| Apr 22, 2026 | Barclays | Maintained | Overweight | $63.00 |
| Apr 21, 2026 | UBS | Maintained | Buy | $60.00 |
| Mar 31, 2026 | Piper Sandler | Maintained | Overweight | $95.00 |
| Mar 30, 2026 | HC Wainwright & Co. | Maintained | Buy | $66.00 |
| Mar 17, 2026 | UBS | Maintained | Buy | $90.00 |
| Mar 12, 2026 | Wedbush | Maintained | Outperform | $75.00 |
| Mar 9, 2026 | Truist Securities | Maintained | Hold | $50.00 |
| Mar 5, 2026 | Stifel | Maintained | Buy | $85.00 |
| Mar 4, 2026 | HC Wainwright & Co. | Maintained | Buy | $66.00 |
| Mar 4, 2026 | Barclays | Maintained | Overweight | $79.00 |

## Frequently Asked Questions

### What is the price target for ANAB stock?

The average 12-month analyst price target for AnaptysBio (ANAB) is $76.50, with a high estimate of $95.00 and a low of $60.00, across 4 analysts.

### Is ANAB a buy, sell, or hold?

Analysts covering AnaptysBio currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for ANAB?

The average price target of $76.50 implies 57.05% upside from the last price of $48.71.

### What is the latest analyst rating on ANAB?

On Sep 30, 2026, JP Morgan maintained AnaptysBio at Overweight with a price target of $60.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).